The first patient is recruited in a randomized, controlled clinical trial of Autologous Tenocyte Injection (Ortho-ATI®) vs. corticosteroid injection to treat rotator cuff tendinopathy. The trial is a collaboration between Orthocell and DePuy Synthes Products.
In previous studies, Ortho-ATI has been shown to be a cost effective, durable, non-surgical solution for hard-to-treat tendon injuries.
The first patient is recruited in a randomized, controlled clinical trial of Autologous Tenocyte Injection (Ortho-ATI®) vs. corticosteroid injection to treat rotator cuff tendinopathy. The trial is a collaboration between Orthocell and DePuy Synthes Products.
In previous studies, Ortho-ATI has been shown to be a cost effective, durable,...
The first patient is recruited in a randomized, controlled clinical trial of Autologous Tenocyte Injection (Ortho-ATI®) vs. corticosteroid injection to treat rotator cuff tendinopathy. The trial is a collaboration between Orthocell and DePuy Synthes Products.
In previous studies, Ortho-ATI has been shown to be a cost effective, durable, non-surgical solution for hard-to-treat tendon injuries.
Copy to clipboard 
